The COPD devices market is expected to grow from US$ 8,849.16 million in 2022 to US$ 12,877.43 million by 2030; it is anticipated to record a CAGR of 4.8% from 2022 to 2030.

Chronic obstructive pulmonary disease, or COPD, refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. The lungs can get damaged or clogged with phlegm in people with COPD. Symptoms include cough, sometimes with phlegm, difficulty breathing, wheezing, and tiredness. Smoking and air pollution are the most common causes of COPD. People with COPD are at higher risk of other health problems. According to the Centers for Disease Control and Prevention (CDC), COPD makes breathing difficult for the 16 million Americans who have this disease. Several inhalation device types are available, including metered-dose inhalers (MDIs), dry-powder inhalers (DPIs), soft mist inhalers (SMIs), and small-volume nebulizers (SVNs). Each device has unique attributes to consider when selecting treatment for a specific patient.

Adopting smart inhalers creates opportunities for the growth of the COPD Devices Market.

Smart inhalers aim to help people with COPD ensure they take their medication as prescribed by recording the timing and dosage on their smartphones. A clinician can use the data collected to verify that the prescribed treatment is working, personalize COPD reviews to focus on the root causes of worsening symptoms and provide early warning systems that inform when to visit a clinic. This technology could shift from one-size-fits-all COPD screening and lead to fewer routine appointments, easing pressure on the National Health Service (NHS). Smart inhalers benefit adults and the geriatric population, as they struggle to take the same puffs due to uneven breathing. The muscles that support breathing and the diaphragm weaken with age, preventing air from inhaling or exhaling. Smart inhalers equipped with sensors can be connected to conventional inhalers and help keep track of when the medication is taken. Being Bluetooth-enabled, they can also be remotely paired with a computer or smart device, such as a phone or tablet, to automatically transfer data from the smart inhaler. In India, the demand for smart inhalers has increased due to the rising prevalence of respiratory diseases, such as COPD, and smoking habits.

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production, and wheezing. It's typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer, and a variety of other conditions. According to the American Lung Association, COPD is the leading cause of death in the US, and more than 12 million Americans were diagnosed with these diseases in 2022. Per the same source, ~8.5 million adults globally were diagnosed with COPD in 2019-2020. According to the World Health Organization (WHO), COPD was the third prominent cause of death worldwide in 2021. The high mortality rate of COPD is associated with acute exacerbations that lead to the failure of patients' respiratory muscles, resulting in the loss of their ability to breathe independently; thus, the patients die from systemic infection and asphyxia. Further, according to the Burden of Obstructive Lung Disease (BOLD) report, 2020, mortality due to COPD is projected to rise worldwide over the next 40 years, reaching 5.4 million deaths annually by 2060. The increasing prevalence of COPD globally is fueling the growth of the COPD devices market.

Based on geography, the COPD devices market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America is the largest contributor to the global COPD devices market growth. Asia Pacific is expected to register the highest CAGR in the COPD devices market from 2022 to 2030. The continuously rising incidence of respiratory disorders is believed to fuel this market's future growth. Currently, chronic obstructive pulmonary disease (COPD) is a major health burden in the US. COPD is due to obstruction of airflow from the lungs, which causes chronic inflammatory lung disease. Smoking is the main cause of COPD in the US. They were increasing smoking in the US, driving the growth of the COPD devices market. According to the Centers for Disease Control and Prevention (CDC), ~14.8 million adults in the US suffer from COPD.

Furthermore, according to the Administration for Community Living, the population 65 years and above in the United States was 54.1 million, contributing to 16% of total population and is expected to reach 21.6% in 2040. The older population is more susceptible to various chronic respiratory diseases. Thus, a continuous rise in the older population is also expected to boost the growth of the respiratory inhaler market during the forecast period. Moreover, favorable reimbursement policies are also expected to create ample opportunities for the growth of the COPD devices market.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Health Services (NHS) are a few key primary and secondary sources referred to while preparing the report on the COPD devices market.